Clinical trials: Advanced Rectal Cancers
Rectal Neoplasms
Fish Oil Supplement in Rectal Cancer
Neoadjuvant treatment with radiotherapy (RDT) and chemotherapy (CT) are the treatment of choice for rectal adenocarcinomas in stages II and III. This results currently in pathologic complete response in 10% to 30% of cases.
- Trial name
- NCT02534389
- Testing
- omega-3 fish oil
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
This phase I trial studies the side effects and the best dose of lenalidomide when given together with cetuximab in treating patients with colorectal cancer or head and neck cancer that has spread to other places in the body and…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma
- Trial name
- ADCC (NCT01254617)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
Background: Metastatic or refractory/recurrent small bowel and colorectal cancers cannot be cured and are often not helped by standard treatments. Researchers want to find better treatments by testing a combination of drugs.
- Trial name
- NCT04491955
- Testing
- CV301, MSB0011359C, N-803
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic…
- Conditions
- Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer
- Trial name
- SPKTAHC (NCT07636785)
- Testing
- VMD-102
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- VM Discovery, Inc.
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Colorectal Cancer, Colorectal Neoplasms
Early Detection of Advanced Adenomas and Colorectal Cancer
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma
- Trial name
- AACRC (NCT06342440)
- Testing
- DENEB
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Rectal Neoplasms
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy With 5-Fluorouracil and Oxaliplatin Versus 5-Fluorouracil Alone in Rectal Cancer
Standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-Fluorouracil (5-FU) plus 4 cycles of postoperative chemotherapy with 5-FU.
- Trial name
- NCT00349076
- Testing
- 5-FU and oxaliplatin, 5-FU
- Where
- 89 sites in Germany
- Volunteers
- 1,256 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Colorectal Cancer
mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer
The current standard treatment for locally advanced rectal cancer is still fluorouracil-based neoadjuvant radiotherapy and chemotherapy followed by TME surgery, followed by adjuvant chemotherapy.
- Trial name
- FANTASTIC (NCT04338191)
- Testing
- mFOLFOXIRI adjuvant chemotherapy, mFOLFOX6 adjuvant chemotherapy
- Where
- China
- Volunteers
- 638 people
- Sponsor
- Sun Yat-sen University
Patient Satisfaction, Quality of Life
Patient Experiences Following Urinary Diversion as Part of Surgery for Advanced and Recurrent Rectal Cancer
The outcomes of patients who undergo radical surgery for locally advanced and recurrent rectal cancer have improved vastly, but there is a lack of emphasis on the quality-of-life outcomes of these patients.
- Conditions
- Patient Satisfaction, Quality of Life, Patient Participation
- Trial name
- Pelvex 3 (NCT04715308)
- Testing
- Urinary diversion
- Where
- Ireland
- Volunteers
- 1,200 people
- Sponsor
- St Vincent's University Hospital, Ireland
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Rectal Cancer
Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens is planned for 15 locally advanced…
- Trial name
- NCT01395667
- Testing
- CCRT
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment
The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer
In this study, we aim to investigate the prognostic value of pre-treatment NLR in patients with locally advenced rectal cancer and post-treatment
- Trial name
- NCT05673343
- Volunteers
- 100 people
- Sponsor
- Assiut University
Advanced Solid Tumor, Advanced Colorectal Carcinoma
Combining Epigenetic And Immune Therapy to Beat Cancer.
Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.
- Conditions
- Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- CAIRE (NCT04705818)
- Testing
- Durvalumab, Tazemetostat
- Where
- 3 sites in France
- Volunteers
- 164 people
- Sponsor
- Institut Bergonié
Organoids, Rectal Cancer
Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer
Patients with locally advanced rectal cancer will receive biopsy before the standard treatment of neoadjuvant chemoradiation. The investigators are going to establish organoids model from the pre-treatment biopsies and expose…
- Conditions
- Organoids, Rectal Cancer, Chemoradiation
- Trial name
- NCT03577808
- Testing
- Biopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhen Zhang
Rectal Cancer, Colorectal Cancer
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
The purpose of this study is to demonstrate the functionality of a novel endorectal photoacoustic ultrasound imaging modality in humans with rectal cancer.
- Trial name
- NCT04339374
- Testing
- Photoacoustic imaging, photoacoustic microscopy, Endorectal photoacoustic imaging probe, Reader Performance
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer
OSI-906 and Irinotecan in Patients With Advanced Cancer
This study plans to learn more about an investigational drug called OSI-906. OSI-906 is being looked at to see if it could be a treatment for advanced cancer. "The FDA is the U.S.
- Trial name
- NCT01016860
- Testing
- OSI-906, irinotecan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Colorectal Cancer, Colorectal Cancer Metastatic
A Study of Famitinib in Patients With Advanced Colorectal Cancer
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, and it's anti-angiogenesis effect has been viewed in preclinical tests. Phase I study has shown that the toxicity is manageable.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
- Trial name
- NCT01762293
- Testing
- Famitinib
- Where
- 2 sites in China
- Volunteers
- 154 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastrointestinal Cancer, Gastrointestinal Neoplasms
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
- Trial name
- NCT03597581
- Testing
- ompenaclid, FOLFIRI, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 89 people
- Sponsor
- Inspirna, Inc.
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.